Silo Pharma, Inc. (SILO) has a negative trailing P/E of -1.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -77.42%.
Criteria proven by this page:
Overall SharesGrow Score: 20/100 with 0/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -0.3 | 0.00 | 0.42 | -0.52 | - |
| 2017 | 1.0 | -0.01 | 0.29 | 0.41 | - |
| 2018 | -0.4 | 0.00 | 0.84 | 0.00 | - |
| 2019 | -0.3 | -0.01 | -12.88 | 7.27 | - |
| 2020 | -0.2 | 0.00 | 0.36 | 0.00 | - |
| 2021 | 0.1 | 0.00 | 0.03 | 3.81 | - |
| 2022 | -2.0 | 0.01 | 0.74 | 106.45 | - |
| 2023 | -1.2 | 0.04 | 0.72 | 61.51 | - |
| 2024 | -0.7 | 0.89 | 0.65 | 45.43 | - |
| 2025 | -0.7 | 0.01 | 0.45 | 39.53 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-1.11 | $-669.48K | $-1.11M | - |
| 2017 | $0.50 | $847.41K | $356.54K | 42.1% |
| 2018 | $-0.99 | $0.00 | $-969.46K | - |
| 2019 | $-1.24 | $40.57K | $-1.05M | -2583.5% |
| 2020 | $-2.37 | $40.92K | $-3.13M | -7648.2% |
| 2021 | $2.03 | $71.26K | $3.9M | 5477.9% |
| 2022 | $-1.71 | $72.1K | $-3.91M | -5420.9% |
| 2023 | $-1.20 | $72.1K | $-3.7M | -5132.6% |
| 2024 | $-1.19 | $72.1K | $-4.39M | -6092.6% |
| 2025 | $-0.50 | $72.1K | $-4.23M | -5863.5% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.72 | $-0.72 – $-0.72 | $72K | $72K – $72K | 1 |
| 2027 | $-1.12 | $-1.12 – $-1.12 | $72K | $72K – $72K | 1 |
| 2028 | $-1.21 | $-1.21 – $-1.21 | $72K | $72K – $72K | 1 |
